BCAX
$19.32
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors.
Recent News
Bicara Therapeutics Talks Ficerasfusp Alfa Data, Pivotal Trial Timeline and $172M Raise at Conference
Bicara Therapeutics (NASDAQ:BCAX) is developing tumor-targeting bifunctional antibodies, with its lead candidate ficerasfusp alfa designed to address both EGFR and TGF-beta biology in cancer, company President and Chief Operating Officer Ryan Cohlhepp said during a conference session moderated by Ba
A Look At Bicara Therapeutics (BCAX) Valuation After New FICERA Clinical Data And Accelerated Approval Plan
Bicara Therapeutics (BCAX) is back on investors’ radar after reporting clinical data for its FICERA program, which showed a 54% overall response rate and a 21% complete response rate, along with plans to pursue accelerated approval. See our latest analysis for Bicara Therapeutics. At a share price of $18.47, Bicara’s recent FICERA update and the completed roughly US$150m follow on offering appear to be drawing attention. The 7 day share price return of 10.07% and 1 year total shareholder...
Bicara Therapeutics Touts FICERA Data, Sets Pivotal FORTIFY Path at TD Cowen Conference
Bicara Therapeutics (NASDAQ:BCAX) outlined its clinical and development strategy for its lead bifunctional antibody program, FICERA, during a presentation and fireside chat at TD Cowen’s 46th annual health care conference. Ryan Cohlhepp, the company’s President and COO, said the company is advancing
Bicara Therapeutics Shares New FICERA Data, Eyes Less Frequent Dosing in Head & Neck Cancer
Bicara Therapeutics (NASDAQ:BCAX) executives reviewed new clinical data for ficerafusp alfa (FICERA) from the 2026 Multidisciplinary Head and Neck Cancer Symposium (MHNCS), highlighting preliminary results from a less frequent dosing regimen and outlining plans to explore a loading-and-maintenance s
Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial
Bicara Therapeutics (NASDAQ:BCAX) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its 2026 corporate outlook and highlight 2025 milestones centered on its lead clinical program, ficerafusp alfa, a bifunctional antibody designed to modulate the tumor microenviron